Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein–Protein Interaction

2021 ◽  
Author(s):  
Zhen Wang ◽  
Min Zhang ◽  
Wen Luo ◽  
Yongqiang Zhang ◽  
Haitao Ji
Keyword(s):  
Acetic Acid ◽  
B Cell ◽  
Small Molecule ◽  
Protein Interaction ◽  
Small Molecule Inhibitors ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Phenoxy Acetic Acid ◽  
Protein Protein Interaction ◽  
Catenin B

Rational Design of Selective Small-Molecule Inhibitors for β-Catenin/B-Cell Lymphoma 9 Protein–Protein Interactions

2015 ◽  
Vol 137 (38) ◽  
pp. 12249-12260 ◽  
Author(s):  
Logan R. Hoggard ◽  
Yongqiang Zhang ◽  
Min Zhang ◽  
Vanja Panic ◽  
John A. Wisniewski ◽  
...  
Keyword(s):  
B Cell ◽  
Small Molecule ◽  
Protein Interactions ◽  
Rational Design ◽  
Small Molecule Inhibitors ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Protein Protein Interactions ◽  
Catenin B

scholarly journals Structure-Based Design of 1,4-Dibenzoylpiperazines as β-Catenin/B-Cell Lymphoma 9 Protein–Protein Interaction Inhibitors

2016 ◽  
Vol 7 (5) ◽  
pp. 508-513 ◽  
Author(s):  
John A. Wisniewski ◽  
Jinya Yin ◽  
Kevin B. Teuscher ◽  
Min Zhang ◽  
Haitao Ji
Keyword(s):  
B Cell ◽  
Protein Interaction ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Protein Protein Interaction ◽  
Catenin B

Structure-based Drug Design Strategies in the Development of Small Molecule Inhibitors Targeting Bcl-2 Family Proteins

2020 ◽  
Vol 17 (8) ◽  
pp. 943-953
Author(s):  
Zhe Yin ◽  
Donglin Yang ◽  
Jun Wang ◽  
Yuequan Jiang
Keyword(s):  
Clinical Trials ◽  
Drug Design ◽  
B Cell ◽  
Cancer Cells ◽  
Small Molecule ◽  
Small Molecule Inhibitors ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Design Strategies ◽  
Structure Based Drug Design

Proteins of B-cell lymphoma (Bcl-2) family are key regulators of apoptosis and are involved in the pathogenesis of various cancers. Disrupting the interactions between the antiapoptotic and proapoptotic Bcl-2 members is an attractive strategy to reactivate the apoptosis of cancer cells. Structure-based drug design (SBDD) has been successfully applied to the discovery of small molecule inhibitors targeting Bcl-2 proteins in past decades. Up to now, many Bcl-2 inhibitors with different paralogue selectivity profiles have been developed and some were used in clinical trials. This review focused on the recent applications of SBDD strategies in the development of small molecule inhibitors targeting Bcl-2 family proteins.

Discovery of a B-Cell Lymphoma 6 Protein–Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach

2017 ◽  
Vol 60 (10) ◽  
pp. 4358-4368 ◽  
Author(s):  
Yusuke Kamada ◽  
Nozomu Sakai ◽  
Satoshi Sogabe ◽  
Koh Ida ◽  
Hideyuki Oki ◽  
...  
Keyword(s):  
B Cell ◽  
Protein Interaction ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Protein Protein Interaction
Sign in / Sign up

Export Citation Format

Share Document